Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
In a Phase 2 trial, patients with early Parkinsons disease taking an older GLP-1 diabetes drug called lixisenatide experienced no worsening of motor symptoms over a year, in contrast to patients on placebo who did, according to the study, published Wednesday in the New England Journal of Medicine
Research has documented effects on approximately 4,000 genes, with 59% being upregulated (turned up) and 41% being downregulated (turned down)
Taper your GLP-1: One option is to taper your GLP-1s instead of just going cold turkey
Discover our Vitamin Injections for energy, immunity, and more.
But it can matter for medications with a narrow therapeutic index ones where the gap between too little and too much is small, and where too little can be as dangerous as too much, says Dr
Consistency is key to maintaining the benefits of GLP-1 therapy
